Skip to main content
. Author manuscript; available in PMC: 2022 Jul 15.
Published in final edited form as: Cancer Res. 2021 Nov 22;82(2):248–263. doi: 10.1158/0008-5472.CAN-21-1991

Figure 2. SCLC Tumors Select for LOF Notch Mutations and In-Frame Deletions to Restore Ascl1 Expression.

Figure 2.

(A-D) Representative examples of CRISPR amplicon sequencing of lung tumors that developed in LSL-Cas9 mice injected with the sgNotch2 RPP (A), sgAscl1 RPP (B) or sgNotch1 RPP (C, D) adenoviruses. sgRNA sequences are labeled in blue within the consensus sequence. Gene editing is highlighted in red. (E, F) CRISPR amplicon sequencing of Notch1, Notch2 or Ascl1 genomic loci from tumors isolated from LSL-Cas9 mice infected with the respective adenoviruses, showing the proportion of mutant and wild-type sequencing reads (E), and the proportion of each type of indel for each tumor (F). FS: frame shift, NFS: non-frame shift. (G) Representative H&E and IHC for Ascl1 in SCLC lung tumors from LSL-Cas9 mice injected with the indicated RPP adenoviruses. Scale Bar=50 μM. (H) Representative IHC for Notch1 and Notch2 from SCLC lung tumors formed in LSL-Cas9 mice injected with the indicated RPP adenoviruses. Scale Bar=50 μM.